Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Determining the Optimal Protocol for Measuring an Albuminuria Class Transition in Clinical Trials in Diabetic Kidney Disease.

Kröpelin TF, de Zeeuw D, Remuzzi G, Bilous R, Parving HH, Heerspink HJ.

J Am Soc Nephrol. 2016 Nov;27(11):3405-3412. Epub 2016 Apr 7.

2.

Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy.

Kröpelin TF, de Zeeuw D, Andress DL, Bijlsma MJ, Persson F, Parving HH, Heerspink HJ.

Clin J Am Soc Nephrol. 2015 Mar 6;10(3):410-6. doi: 10.2215/CJN.07780814. Epub 2015 Jan 7.

3.

Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis.

Heerspink HJ, Kröpelin TF, Hoekman J, de Zeeuw D; Reducing Albuminuria as Surrogate Endpoint (REASSURE) Consortium.

J Am Soc Nephrol. 2015 Aug;26(8):2055-64. doi: 10.1681/ASN.2014070688. Epub 2014 Nov 24. Review.

4.

Fall determinants in older long-term care residents with dementia: a systematic review.

Kröpelin TF, Neyens JC, Halfens RJ, Kempen GI, Hamers JP.

Int Psychogeriatr. 2013 Apr;25(4):549-63. doi: 10.1017/S1041610212001937. Epub 2012 Dec 20. Review.

PMID:
23253253

Supplemental Content

Loading ...
Support Center